Itraconazole Solid Dispersion Melt Extrusion Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing pharmaceutical compositions of itraconazole with improved bioavailability remains a challenge due to its insolubility in aqueous media, despite previous advancements in melt-extruded compositions with hydroxypropyl methylcellulose, as higher bioavailability goals have not been fully met.
Innovation Solution
A solid dispersion product is created through a melt-extrusion process combining itraconazole and hydroxypropyl methylcellulose, with specific conditions optimizing the endotherm change rate (ΔHtr) between 0.35 and 0.15 J/g at 240-250 °C, ensuring a homogeneous matrix for enhanced dissolution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If itraconazole is formulated using conventional methods, then manufacturing is simple, but bioavailability is poor due to insolubility in aqueous media
Solution Approach 1:
The patent changes the physical state parameter of itraconazole from crystalline to amorphous form through melt extrusion processing. This parameter change increases solubility and bioavailability without requiring complex formulation techniques, resolving the contradiction between improving bioavailability and maintaining formulation simplicity.
Solution Approach 2:
The patent creates a composite material system by combining itraconazole with hydroxypropyl methylcellulose (HPMC) through melt extrusion. The HPMC matrix provides a favorable environment for the amorphous itraconazole, enhancing dissolution and bioavailability while maintaining a relatively simple two-component formulation.
2Reliability
If melt extrusion is used to improve dissolution rate, then bioavailability increases, but manufacturing precision requirements increase to control endotherm parameters
Solution Approach 1:
The patent uses differential scanning calorimetry (DSC) to measure the endotherm parameter ΔHtr as a feedback indicator of processing quality. By establishing target ranges for ΔHtr (0.15-0.35 J/g), the process enables quality control through measurement and adjustment, ensuring consistent dissolution rates while managing manufacturing precision requirements.
Solution Approach 2:
The melt extrusion process serves multiple functions simultaneously: it creates the amorphous state, ensures homogeneous distribution of itraconazole in the HPMC matrix, and produces a formulation with controlled dissolution properties. This multi-functionality reduces the need for additional processing steps while maintaining manufacturing feasibility.
3Reliability
If energy input during melt extrusion is increased to optimize dispersion, then bioavailability improves, but energy consumption increases
Solution Approach 1:
The patent applies partial action by using just sufficient energy input to achieve the desired amorphous state and homogeneous dispersion, as indicated by the optimized ΔHtr range. Rather than excessive energy input, the process uses minimal necessary energy to transform the crystalline material into the amorphous state, balancing dispersion quality with energy efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in a formulation with significantly improved bioavailability, allowing for rapid dissolution and effective antifungal activity, with the energy input during melt-extrusion being a critical parameter for achieving optimal dispersion and bioavailability.
Implementation Method 1
a solid dispersion product, obtainable by a melt-extrusion process, comprising itraconazole and hydroxypropyl methylcellulose
Implementation Method 2
The term 'solid dispersion' defines a system in a solid state comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component
Implementation Method 3
The ΔH tr is determined by differential scanning calorimetry (DSC) measurement
Implementation Method 4
the endotherm between -20 °C and 300 °C is obtained by heating the sample at a temperature rise rate of 10°C/minute. A maximum peak is observed in the thus prepared melting endotherm curve in the range of from about 240 °C to about 250 °C
Data Source
Figure 1
AI summary
A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35 > ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.